Oral Therapies in Psoriasis Management: A Debate on Deucravacitinib vs Apremilast - Episode 6
A Closer Look at Safety and Tolerability for Deucravacitinib and Apremilast in Psoriasis
Panelists discuss how both oral agents exhibit reassuring long-term safety and tolerability that support continued use in diverse psoriasis populations.
Panelists discuss how safety remains central to therapy selection, especially for long-term psoriasis management. Both deucravacitinib and apremilast show favorable profiles, with no significant organ toxicity or lab monitoring burdens. Deucravacitinib maintains a consistent safety record over 5 years, while apremilast’s profile is well characterized across psoriasis and related conditions.
Panelists discuss how tolerability drives adherence. Apremilast’s gastrointestinal effects often resolve over time, while deucravacitinib’s selective mechanism minimizes off-target adverse events. These aspects contribute to sustained treatment satisfaction and persistence.
Panelists discuss how safety considerations differ by comorbidity and patient preference. The experts encourage clinicians to engage patients in open discussions about risks, benefits, and expectations to ensure long-term therapeutic success.
